We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

BioE®, Inc. and M. D. Anderson Cancer Center Form Research Partnership

BioE®, Inc. and M. D. Anderson Cancer Center Form Research Partnership

BioE®, Inc. and M. D. Anderson Cancer Center Form Research Partnership

BioE®, Inc. and M. D. Anderson Cancer Center Form Research Partnership

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioE®, Inc. and M. D. Anderson Cancer Center Form Research Partnership"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioE®, Inc. and The University of Texas M. D. Anderson Cancer Center has announced a research partnership to evaluate the potential of BioE’s cord blood stem cell; the Multi-Lineage Progenitor Cell™ (MLPC™); to help treat cancer.

Specifically, BioE and M. D. Anderson will collaborate to determine the MLPC’s utility as an anti-tumor protein delivery vehicle.

M. D. Anderson has used bone marrow-derived stem cells to transport anti-tumor proteins, such as interferon-beta (IFN-ß) and interferon-alpha (IFN-a), to a tumor site in animal models. During these early studies, researchers suppressed the growth of tumors and the advancement of chronic myeloid leukemia.

“Our research suggests stem cells have an inherent ability to contribute to the microenvironment of tumors independent of histology or location, and can be manipulated to express anti-tumor genes,” said Michael Andreeff, M.D., Ph.D., professor, M. D. Anderson’s Department of Stem Cell Transplantation and Cellular Therapy.

“As a result, utilizing stem cells as a tool for delivering anti-tumor proteins has great potential for broad application in oncology. We are particularly excited to work with BioE’s clonal, cord blood-derived MLPC to ascertain if it’s an easily accessible and suitable alternative cell type for transporting anti-tumor proteins. Hopefully, this research and targeted approach for anti-tumor protein delivery can be developed into a new therapeutic modality for cancer therapy,” Andreeff said.

“We are eager to work with one of the nation’s preeminent cancer centers and Dr. Andreeff’s group as the application and use of our highly functional MLPC expands into oncology,” said Michael Haider, president and chief executive officer for BioE.

“Using our stem cell as a tool to more effectively transport anti-tumor proteins directly into a tumor is very promising and further demonstrates the MLPC’s broad utility. We believe this oncology research will lead to additional studies examining the MLPC’s ability to deliver various gene therapies throughout the human body and look forward to exploring this type of research in the coming months.”